184 related articles for article (PubMed ID: 21584928)
1. Which matters most: number of tumors, size of the largest tumor, or total tumor volume?
Germani G; Gurusamy K; Garcovich M; Toso C; Fede G; Hemming A; Suh KS; Weber A; Burroughs AK
Liver Transpl; 2011 Oct; 17 Suppl 2():S58-66. PubMed ID: 21584928
[No Abstract] [Full Text] [Related]
2. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
Grant D; Fisher RA; Abecassis M; McCaughan G; Wright L; Fan ST
Liver Transpl; 2011 Oct; 17 Suppl 2():S133-8. PubMed ID: 21634006
[No Abstract] [Full Text] [Related]
3. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation.
Kneteman N; Livraghi T; Madoff D; de Santibañez E; Kew M
Liver Transpl; 2011 Oct; 17 Suppl 2():S117-27. PubMed ID: 21584926
[No Abstract] [Full Text] [Related]
4. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Davis E; Wiesner R; Valdecasas J; Kita Y; Rossi M; Schwartz M
Liver Transpl; 2011 Oct; 17 Suppl 2():S162-6. PubMed ID: 21688382
[No Abstract] [Full Text] [Related]
5. Selection criteria for patients with hepatocellular carcinoma in liver transplantation.
Kaido T; Takada Y; Uemoto S
Transplantation; 2009 Aug; 88(3):442-3; author reply 443. PubMed ID: 19667951
[No Abstract] [Full Text] [Related]
6. Effects of risk factors and Ki-67 on rates of recurrence on patients who have undergone liver transplant for hepatocellular carcinoma.
Aktas S; Karakayali H; Moray G; Ozdemir H; Haberal M
Transplant Proc; 2011 Dec; 43(10):3807-12. PubMed ID: 22172851
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression and hepatocellular carcinoma.
Schlitt HJ; Mornex F; Shaked A; Trotter JF
Liver Transpl; 2011 Oct; 17 Suppl 2():S159-61. PubMed ID: 21506251
[No Abstract] [Full Text] [Related]
8. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients.
Ataide EC; Boin IF; Almeida JR; Sevá-Pereira T; Stucchi RS; Cardoso AR; Caruy CA; Escanhoela CA
Transplant Proc; 2011 May; 43(4):1362-4. PubMed ID: 21620130
[TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for hepatocellular carcinoma: the best treatment, but for which patient?
Schwartz ME
Hepatology; 1996 Dec; 24(6):1539-41. PubMed ID: 8938193
[No Abstract] [Full Text] [Related]
10. Living donor liver transplantation in patients who have received pretransplant treatment for hepatocellular carcinoma.
Yoshizumi T; Shirabe K; Soejima Y; Taketomi A; Ikegami T; Uchiyama H; Harada N; Ijichi H; Maehara Y
Transplantation; 2011 Apr; 91(8):e61-2. PubMed ID: 21475066
[No Abstract] [Full Text] [Related]
11. Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: the lower, the better!
You H; Jia JD
J Gastroenterol Hepatol; 2010 Dec; 25(12):1812-4. PubMed ID: 21091989
[No Abstract] [Full Text] [Related]
12. Should we perform deceased donor liver transplantation after living donor liver transplantation has failed?
Greig PD; Geier A; D'Alessandro AM; Campbell M; Wright L
Liver Transpl; 2011 Oct; 17 Suppl 2():S139-46. PubMed ID: 21563294
[No Abstract] [Full Text] [Related]
13. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.
Mazzaferro V; Bhoori S; Sposito C; Bongini M; Langer M; Miceli R; Mariani L
Liver Transpl; 2011 Oct; 17 Suppl 2():S44-57. PubMed ID: 21695773
[No Abstract] [Full Text] [Related]
14. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?
Duvoux C; Kiuchi T; Pestalozzi B; Busuttil R; Miksad R
Liver Transpl; 2011 Oct; 17 Suppl 2(Suppl 2):S147-58. PubMed ID: 21714065
[No Abstract] [Full Text] [Related]
15. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
Decaens T; Roudot-Thoraval F; Badran H; Wolf P; Durand F; Adam R; Boillot O; Vanlemmens C; Gugenheim J; Dharancy S; Bernard PH; Boudjema K; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Hilleret MN; Chazouillères O; Cherqui D; Mallat A; Duvoux C
Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209
[TBL] [Abstract][Full Text] [Related]
16. Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma.
Kim SJ; Lee KK; Kim DG
Hepatogastroenterology; 2010; 57(97):121-6. PubMed ID: 20422886
[TBL] [Abstract][Full Text] [Related]
17. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?
Yao FY; Breitenstein S; Broelsch CE; Dufour JF; Sherman M
Liver Transpl; 2011 Oct; 17 Suppl 2():S109-16. PubMed ID: 21584927
[No Abstract] [Full Text] [Related]
18. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation.
Löhe F; Angele MK; Rentsch M; Graeb C; Gerbes A; Löhrs U; Beuers U; Jauch KW
Clin Transplant; 2007; 21(6):696-701. PubMed ID: 17988261
[TBL] [Abstract][Full Text] [Related]
19. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?
Olthoff KM; Forner A; Hübscher S; Fung J
Liver Transpl; 2011 Oct; 17 Suppl 2():S26-33. PubMed ID: 21656653
[No Abstract] [Full Text] [Related]
20. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program.
Nemes B; Gelley F; Piros L; Zádori G; Görög D; Fehérvári I; Kóbori L; Sárváry E; Nagy P; Kiss A; Doros A
Transplant Proc; 2011 May; 43(4):1272-4. PubMed ID: 21620108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
